InMode Ltd.

NasdaqGS:INMD Aktierapport

Börsvärde: US$888.3m

InMode Framtida tillväxt

Future kriterier kontrolleras 0/6

InMode s intäkter förväntas minska med 0.6% per år medan dess årliga intäkter förväntas växa med 1.5% per år. EPS förväntas tillväxt med 0.3% per år.

Viktig information

-0.6%

Tillväxttakt i vinsten

0.28%

Tillväxttakt för EPS

Medical Equipment vinsttillväxt16.1%
Intäkternas tillväxttakt1.5%
Framtida avkastning på eget kapitaln/a
Bevakning av analytiker

Good

Senast uppdaterad08 May 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Uppdatering av berättelse • May 03

INMD: Buyback Plan And 2026 Guidance Will Support A Measured Outlook

Analysts kept their $15.00 price target for InMode unchanged, noting only minor shifts in inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the basis for maintaining their view. What's in the News InMode issued revenue guidance for the first quarter of 2026, with expected revenue in a range of $81.5 million to $81.7 million, and reiterated its full year 2026 revenue outlook of $365 million to $375 million (Corporate Guidance).
Uppdatering av berättelse • Apr 19

INMD: Takeover Talks And Buyback Plan Will Shape A Measured Outlook

InMode's updated analyst price target remains at $15.00, with analysts pointing to small shifts in the discount rate, revenue growth assumptions, profit margin, and future P/E as the key drivers behind the reaffirmed valuation view. What's in the News Media report that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, pointing to ongoing interest from financial buyers (Calcalist).
Uppdatering av berättelse • Apr 03

INMD: Potential Takeover Talks And Buyback Plan Will Shape A Balanced Outlook

Analysts have maintained their $15.00 price target for InMode, citing small adjustments to assumptions such as the discount rate, revenue growth, profit margin, and future P/E that did not materially affect their overall valuation view. What's in the News Media reports indicate InMode is in talks to be sold for about US$1.1b to a foreign investment fund, highlighting ongoing interest from financial buyers (Calcalist).
Uppdatering av berättelse • Mar 20

INMD: Potential Sale Talks And Buyback Plan Will Shape A Measured Outlook

Analysts have kept their $15.00 price target on InMode unchanged, citing only very small tweaks to model inputs around discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their view of the stock. What's in the News Media report that InMode is in talks to be sold for about US$1.1 billion to a foreign investment fund, according to Calcalist (Calcalist).
Uppdatering av berättelse • Mar 05

INMD: Potential Sale And Earnings Guidance Will Shape A Measured Forward View

Analysts have kept their $15.00 price target on InMode unchanged, citing only marginal tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that did not materially alter their overall view of the stock. What's in the News Calcalist reports that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, indicating ongoing interest in potential ownership changes (Calcalist).
Uppdatering av berättelse • Feb 19

INMD: Potential Sale Talks And Earnings Guidance Will Shape A Balanced Outlook

Analysts kept their $15.00 price target for InMode steady, citing only slight adjustments in assumptions such as discount rate, revenue growth, profit margin, and future P/E as reasons for maintaining their view rather than making a material change. What's in the News Media report that InMode is in talks to be sold for about US$1.1b to a foreign investment fund, according to Calcalist (Periodical).
Seeking Alpha • Feb 18

InMode: Some Green Shoots Appearing, But The Market Hasn't Noticed

Summary InMode Ltd. remains a Strong Buy at current levels, supported by a robust balance sheet, proprietary technology, and international growth. Green shoots include a 2.7% rise in consumables/servicing revenue and 14.5% international sales growth, offsetting possible U.S. market saturation. Management guides for flat 2026 revenue, with new product launches and expanding international footprint positioning INMD for future upside. Despite management frustrations and takeover rumors, INMD's very low valuation and strong cash position offer compelling risk-reward for recovery-focused investors. Read the full article on Seeking Alpha
Uppdatering av berättelse • Feb 04

INMD: Potential Sale Talks And Guidance Will Sustain A Cautious Fair Value View

Analysts have kept their price target for InMode steady at US$15.00, with only minor model tweaks to the discount rate, revenue growth, profit margin and assumed future P/E feeding into this unchanged view. What's in the News Media report that InMode is in talks to be sold to a foreign investment fund in a transaction valued at about US$1.1 billion, indicating active interest in the company from financial buyers (Periodical, Calcalist).
Uppdatering av berättelse • Jan 21

INMD: Refreshed Guidance And Margin Outlook Will Support A Cautious Fair Value Stance

Analysts now see InMode's fair value holding at $15.00. The refreshed price target framework mainly reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in the headline valuation level.
Analysartikel • Jan 07

InMode (NASDAQ:INMD) Could Be Struggling To Allocate Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
Uppdatering av berättelse • Jan 06

INMD: Reaffirmed 2025 Revenue Guidance Will Underpin A Cautious Fairly Valued Outlook

Analysts have nudged their price target on InMode slightly higher to US$15.00 from US$15.00. This reflects small tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E that, in their view, modestly refine rather than overhaul the prior outlook.
Uppdatering av berättelse • Dec 13

INMD: Revenue Outlook And Legal Overhang Will Shape A Cautious 2025 Outlook

Analysts have raised their price target on InMode by 1.00 dollar, reflecting improved expectations for a return to modest top line growth and slightly higher long term profitability multiples. What's in the News InMode reaffirmed its full year 2025 revenue outlook, maintaining guidance at $365 million to $375 million.
Analysartikel • Nov 12

There Might Be More To InMode's (NASDAQ:INMD) Story Than Just Weak Earnings

Shareholders didn't appear too concerned by InMode Ltd.'s ( NASDAQ:INMD ) weak earnings. We did some digging, and we...
Analysartikel • Jul 31

Should You Think About Buying InMode Ltd. (NASDAQ:INMD) Now?

InMode Ltd. ( NASDAQ:INMD ), might not be a large cap stock, but it saw significant share price movement during recent...
Analysartikel • Jun 30

An Intrinsic Calculation For InMode Ltd. (NASDAQ:INMD) Suggests It's 36% Undervalued

Key Insights InMode's estimated fair value is US$22.05 based on 2 Stage Free Cash Flow to Equity InMode's US$14.19...
Analysartikel • May 21

InMode (NASDAQ:INMD) Might Be Having Difficulty Using Its Capital Effectively

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Seeking Alpha • Apr 29

InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)

Summary InMode's Q1 2025 earnings reveal a 3% YoY revenue decline and margin compression, signaling continued macroeconomic pressures and underutilization of installed platforms. Management's revised 2025 guidance lowers profitability expectations, reflecting ongoing challenges in the U.S. market and less profitable international expansion. Despite a strong balance sheet, past strategic missteps and ineffective cash allocation raise concerns about future shareholder value and growth prospects. Given the revenue declines and strategic uncertainties, I downgrade InMode to Hold, recommending caution until significant positive developments occur. Read the full article on Seeking Alpha
Analysartikel • Apr 26

Is Now The Time To Look At Buying InMode Ltd. (NASDAQ:INMD)?

While InMode Ltd. ( NASDAQ:INMD ) might not have the largest market cap around , it saw a decent share price growth of...
Analysartikel • Apr 11

Investors Don't See Light At End Of InMode Ltd.'s (NASDAQ:INMD) Tunnel And Push Stock Down 25%

InMode Ltd. ( NASDAQ:INMD ) shares have had a horrible month, losing 25% after a relatively good period beforehand...
Seeking Alpha • Feb 10

InMode: Plastic Surgery Boom, Cash Flow, And Cheap

Summary InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits from the booming non-invasive plastic surgery market, expected to grow at a 14% CAGR from 2023 to 2030. INMD's stock repurchase program and substantial investments in bonds and bank deposits are expected to boost stock price and financial stability. Despite lower 2024 revenue, new product launches and international efforts indicate promising growth potential from 2025 to 2031. Read the full article on Seeking Alpha
Seeking Alpha • Jan 28

InMode: A Clear Bargain With Unique Risks

Summary InMode Ltd. boasts superior fundamentals, yet trades at undervalued market multiples due to its unique risk profile. The company is a leader in the global aesthetics market with proprietary RF-based technologies. InMode's robust balance sheet and high profit margins support a substantial margin of safety at current prices, despite risks. Read the full article on Seeking Alpha
Analysartikel • Jan 08

An Intrinsic Calculation For InMode Ltd. (NASDAQ:INMD) Suggests It's 50% Undervalued

Key Insights InMode's estimated fair value is US$34.79 based on 2 Stage Free Cash Flow to Equity Current share price of...
Seeking Alpha • Dec 12

InMode: Product Origination And Undervaluation Make The Stock A Buy

Summary InMode Ltd. demonstrates impressive net income growth from non-invasive surgical products, with new platforms Define and Envision expected to drive future business growth. The company's innovative technologies in plastic surgery, dermatology, gynecology, and ophthalmology, along with ongoing stock repurchases, make InMode a compelling buy. Strong financials show consistent income growth and significant cash flow, with minimal liabilities, indicating a robust financial position and undervaluation. Expansion into new markets, enhanced sales force, and continuous R&D in new treatment areas promise sustained revenue and free cash flow growth. Read the full article on Seeking Alpha
Seeking Alpha • Nov 05

InMode: $25/Share Is Closer Than You Think

Summary Elevated interest rates continue to hurt InMode’s revenue, especially as lease package interest rates haven't fallen yet. Still, future rate cuts could release pent-up demand. InMode continues to buy back shares at a low price, which will boost per-share results. InMode's manufacturing is done in Israel, presenting a risk, but the company has been managing this well despite the war. The stock is undervalued, with only modest FCF/share growth needed to achieve a $25 fair value. And this FCF/share growth can be supported by more buybacks. Organizational shifts don't have me worried at the moment, but they are worth monitoring because they present uncertainty. Read the full article on Seeking Alpha
Analysartikel • Nov 01

InMode Ltd. Just Recorded A 17% EPS Beat: Here's What Analysts Are Forecasting Next

InMode Ltd. ( NASDAQ:INMD ) investors will be delighted, with the company turning in some strong numbers with its...
Analysartikel • Sep 24

InMode (NASDAQ:INMD) Could Be Struggling To Allocate Capital

To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...
User avatar
Ny berättelse • Sep 24

Innovations And Global Expansion Poised To Propel Medical Tech Leader To New Heights

Introduction of IgniteRF and Optimus Max platforms, alongside FDA clearance for Morpheus8, drives revenue growth through market penetration and expanding patient base.
Seeking Alpha • Sep 19

InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)

Summary InMode’s Q2 2024 revenue dropped by 36.5% year-over-year to $86.4 million, underlining macroeconomic challenges. The company revised its full-year 2024 revenue guidance to $430-$440 million due to slower platform rollouts and production delays. Lower interest rates from Federal Reserve cuts could boost demand for InMode's minimally invasive treatments, benefiting from reduced financing costs. New platforms IgniteRF and OptimasMAX are expected to drive future growth, appealing to clinics seeking cost-effective solutions. Despite short-term revenue declines, InMode’s attractive valuation and new growth catalysts position it as a "buy" opportunity. Read the full article on Seeking Alpha
Seeking Alpha • Sep 06

InMode Stock: An Inverse Bubble Caused By Short-Term Trouble

Summary InMode stock has significant upside potential due to its low valuation, profitability, share buybacks, and potential benefits from expected interest rate cuts. INMD's business model involves selling high-quality, expensive medical devices for aesthetic procedures, heavily influenced by interest rates due to customer financing. The stock's decline was driven by underutilized buybacks, declining revenue, and high interest rates, but recent buybacks and potential rate cuts offer a brighter outlook. Despite geopolitical risks, InMode's strong cash position, profitability, and the growing aesthetics market make it a long-term investment opportunity. Read the full article on Seeking Alpha
Seeking Alpha • Aug 12

InMode: Still Undervalued, But Short-Term Risks Warrant Caution (Rating Downgrade)

Summary Despite INMD being down -22% since I recommended to Buy the stock in March, InMode Ltd. remains a highly profitable & innovative leader in the aesthetic industry. Stronger than expected macroeconomic pressures and the slow but continuing escalation of the conflict in the Middle-East keep pushing the stock lower. Although I believe INMD remains significantly undervalued, the unpredictable situation in Israel as well as a probable FY2024 guidance miss are key risks that warrant caution. I am therefore downgrading INMD to Hold. I remain long for the mid-term upside potential, but I don’t expect upside catalysts before 2025. Read the full article on Seeking Alpha
Analysartikel • Aug 04

Here's What Analysts Are Forecasting For InMode Ltd. (NASDAQ:INMD) Following Its Earnings Miss

InMode Ltd. ( NASDAQ:INMD ) missed earnings with its latest second-quarter results, disappointing overly-optimistic...
Seeking Alpha • Jun 13

InMode: Reversing Previous Shareholder Dilution With Buybacks

Summary Shareholders of InMode Ltd. have seen a 46% decline in value due to slowing sales and capital allocation uncertainties. Sales growth has been impacted by rising interest rates affecting leasing deals, leading to lower revenue growth projections for 2024. The company's new share repurchase program should reverse the dilution shareholders previously experienced. The low expectations embedded into the company's valuation makes it ripe for a revision higher. Read the full article on Seeking Alpha
Analysartikel • May 29

Lacklustre Performance Is Driving InMode Ltd.'s (NASDAQ:INMD) Low P/E

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 18x, you may...
Seeking Alpha • May 08

InMode: Facing A Myraid Of Headwinds

Summary InMode's growth has plummeted due to sales execution issues, manufacturing delays, reduced demand, and high interest rates. INMD's business seems heavily reliant on economic conditions, beyond management's control. Shareholders expressed frustration with management's capital allocation decisions. I rate the company as a hold for now. Read the full article on Seeking Alpha
Seeking Alpha • Apr 27

InMode: More Headwinds Than Expected, Wait For A Floor To Materialize (Rating Downgrade)

Summary The market remains pessimistic about INMD's prospects, as observed in the stock's decline by -21.6% over the past three months, well underperforming the wider market at +4.7%. Part of the headwinds are attributed to the management's lowered FY2024 revenue guidance, building upon the FY2023 slowdown, as borrowing costs are still elevated for prospective buyers. Then again, we believe that consumer demand for skin-tightening devices and body contouring products may remain robust, thanks to the popularity of GLP-1 obesity therapies. The same has been observed in INMD's growing consumable sales, with it likely to drive intermediate-term growth as equipment sales temporarily stall. However, with the stock recording elevated short interest and the market experiencing an uncertain pullback, it may be more prudent to wait for a floor to materialize first. Read the full article on Seeking Alpha
Seeking Alpha • Apr 03

InMode's Quest For Growth Amidst Aesthetic Adversities

Summary InMode's Q4 revenue dropped YOY; management optimistic about new platforms despite industry challenges. High dependence on U.S. revenue from minimally invasive procedures; facing increasing competition in RF technology. R&D spending at 3% of revenue, below industry norm; sales and marketing costs rising. Investment stance: Hold, pending revenue diversification and increased R&D investment focus. Read the full article on Seeking Alpha
Seeking Alpha • Mar 26

InMode Does Not Look Pretty Right Now: Time To Buy

Summary Despite a highly profitable business model and a strong position in the medical aesthetics industry, INMD stock is down -33% over the last 12 months. Macroeconomic pressures, political risks in InMode’s home country Israel, and, to a lesser extent, suboptimal capital allocation have caused the stock to plummet. InMode continues to deliver cutting-edge innovation and expand its commercial capabilities, steadily gaining market share. Even without a share buyback program, INMD is grossly undervalued unless you believe the conflicts in Israel will escalate. With a fair value of $31 (range $25 to $39), it is time to buy INMD while most investors paint an ugly outlook for this aesthetics leader. Read the full article on Seeking Alpha
Seeking Alpha • Feb 16

InMode: Q4 Earnings Beat Not Enough - Macro Outlook Key To Buy Signal

Summary InMode beats revenue and EPS estimates in Q4 2023 earnings report. Q4 revenue is down 5% YoY and non-GAAP EPS is down 9% YoY. InMode maintains impressive gross margin of 84% and sees 20% YoY growth in revenue from consumables and services. Despite beating the lowered Q4 2023 expectations, InMode is facing challenging conditions with a weak 2024 outlook. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:INMD - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/20283898380824
12/31/20273797978796
12/31/20263707382836
3/31/2026375878687N/A
12/31/2025370948485N/A
9/30/20253641509495N/A
6/30/2025402179104105N/A
3/31/2025392176122123N/A
12/31/2024395181132133N/A
9/30/2024424154161161N/A
6/30/2024417149168169N/A
3/31/2024466181179180N/A
12/31/2023492198176177N/A
9/30/2023499180172173N/A
6/30/2023497183176177N/A
3/31/2023474171169171N/A
12/31/2022454162180182N/A
9/30/2022431176176177N/A
6/30/2022404172181182N/A
3/31/2022378169181182N/A
12/31/2021358165174175N/A
9/30/2021322148163164N/A
6/30/2021288128143143N/A
3/31/2021231959798N/A
12/31/2020206757979N/A
9/30/2020178586465N/A
6/30/2020158504848N/A
3/31/2020166576566N/A
12/31/201915661N/A62N/A
9/30/201913841N/A44N/A
6/30/201912434N/A38N/A
3/31/201911026N/A32N/A
12/31/201810022N/A37N/A
9/30/20189125N/A33N/A
6/30/20188019N/A30N/A
3/31/20186512N/A20N/A
12/31/2017538N/A15N/A
12/31/2016230N/A3N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: INMD s intäkter förväntas minska under de kommande 3 åren ( -0.6% per år).

Resultat vs marknad: INMD s intäkter förväntas minska under de kommande 3 åren ( -0.6% per år).

Höga tillväxtresultat: INMD s intäkter förväntas minska under de kommande 3 åren.

Intäkt vs marknad: INMD s intäkter ( 1.5% per år) förväntas växa långsammare än marknaden för US ( 11.7% per år).

Hög tillväxtintäkter: INMD s intäkter ( 1.5% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: Otillräcklig data för att avgöra om INMD s avkastning på eget kapital förväntas bli hög om tre år

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/21 06:06
Aktiekurs vid dagens slut2026/05/21 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

InMode Ltd. bevakas av 11 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
null nullBaird
Jeffrey JohnsonBaird
Travis SteedBarclays